The Kremlin is still refusing to confirm speculation but quietly removed a rule that exempted fathers with three or more children from mobilization
The Kremlin is still refusing to confirm speculation but quietly removed a rule that exempted fathers with three or more children from mobilization
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Boston, DeepVerge, Europa, Harvest, MyHealth, Mila,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Arc, Borders, Boston, Chill, Clontarf, Card,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Boston, Drumz, Empire, Genedrive, Keras, Live,
Russian technology executive with links to the Kremlin has pleaded not guilty U.S. to charges that led to an insider trading ring that made multi-millions of dollars hacking into systems
On September 2nd, Tiziana Life Sciences PLC (NASDAQ:TLSA) (LSE:TILS) announced an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL) for the exploration and development of foralumab as a lymphodepletion agent to
Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
London/New York, 3 September 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Old Tiziana”) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Zak Mir takes a technical analysis look at some of the most followed small caps on the London market. Today’s selection includes African Pioneer, Boston, BATM, Cora, East Imperial, Emmerson,
London/New York, August 20, 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Old Tiziana”) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases